SEP
DXCM icon

Signature Equity Partners’s DexCom DXCM Stock Holding History

Signature Equity Partners’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9K Sell
221
-20
-8% -$1.33K 0.01% 738
2026
Q1 		$15.1K Buy
241
+107
+80% +$7.45K 0.01% 712
2025
Q4 		$8.89K Buy
+134
New +$8.66K ﹤0.01% 844

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Signature Equity Partners's DXCM Position: Q2 2026 in Review

Signature Equity Partners reduced its DexCom (DXCM) stake by 8.3% in Q2 2026, selling an estimated $1.33K and leaving 221 shares worth $14.9K. The position accounts for 0.01% of the portfolio, ranked #738.

Signature Equity Partners first reported a position in DXCM in Q4 2025 and has held it in 3 quarters since. The position peaked at $15.1K in Q1 2026. 970 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Signature Equity Partners held 221 shares of DexCom worth $14.9K as of Q2 2026.
  • Signature Equity Partners sold 20 DexCom shares in Q2 2026, an estimated $1.33K.
  • DexCom made up 0.01% of Signature Equity Partners's portfolio in Q2 2026, its #738 holding.
  • Signature Equity Partners first reported a position in DexCom in Q4 2025 and has held it in 3 quarters since.
  • Signature Equity Partners's DexCom position peaked at $15.1K in Q1 2026.
  • 970 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.